You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

244 Results
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and No Prior mTOR Inhibitor
New Drug Funding Program
    Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and Prior mTOR Inhibitor
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Regimen
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck which is Platinum Resistant or Refractory
Regimen
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Neoadjuvant
Funding:
ODB - General Benefit
    capecitabine
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019

Pages